- /
- Supported exchanges
- / US
- / UTHR.NASDAQ
United Therapeutics Corporation (UTHR NASDAQ) stock market data APIs
United Therapeutics Corporation Financial Data Overview
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with United Therapeutics Corporation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get United Therapeutics Corporation data using free add-ons & libraries
Get United Therapeutics Corporation Fundamental Data
United Therapeutics Corporation Fundamental data includes:
- Net Revenue: 3 155 M
- EBITDA: 1 496 M
- Earnings Per Share: 27
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get United Therapeutics Corporation Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: 6.82
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
United Therapeutics Corporation News
New
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Shares of Liquidia Corporation LQDA have lost 15.4% since the company reported second-quarter results on Aug. 11. Liquidia reported second-quarter 2026 earnings of 74 cents per share, which beat the ...
Quant ratings on Renaissance Technologies top holdings: NVDA, META, INTC
Renaissance Technologies, founded by Jim Simons, made several changes to its holdings between Q1 and Q2 2026. The quantitative investment firm outperformed the S&P 500 in Q2, returning [https://hedgef...
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
Approximately 200,000 patients in the United States have PPF, with limited treatment options Topline data expected in the second half of 2027 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., Augus...
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
United Therapeutics's Q2 Earnings Call: Our Top 5 Analyst Questions United Therapeutics reported second quarter results that modestly exceeded Wall Street's revenue and adjusted EPS expectations, wit...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.